E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Postoperative pain after hip surgery |
|
E.1.1.1 | Medical condition in easily understood language |
Postoperative pain after hip surgery |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10022891 |
E.1.2 | Term | Investigations |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the success of the transversals fascia plane (TFP) block in producing cutaneous anesthesia proximal to - and continous with - the area of anesthesia produced by the lateral femoral cutaneous nerve (LFCN) block |
|
E.2.2 | Secondary objectives of the trial |
-Evaluating the cutaneous anesthesia after a selective subcostal nerve block -Evaluating the cutaneous anesthesia after the TFP block |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥ 18 years - Written informed consent - ASA i or II -Mentally capable of cooperating during the trial. - Understanding and speaking Danish or English. |
|
E.4 | Principal exclusion criteria |
- Pre-existing neurological pathology involving the area of investigation -Anatomical or mental aspects that would hinder nerve blocks - Allergy to local anesthetics - Current pregnancy - Weight less than 55 kg - Request to leave the trial - Infection in the area of injection |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Success rate of the TFP block with local anesthetic to produce a cutaneous area of anesthesia that is continous with the anesthetized cutaneous area after a LFCN block, compared to placebo. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
30 minutes after relevant nerve blocks |
|
E.5.2 | Secondary end point(s) |
- Time needed to do the subcostal nerve block - Succes rate of ultrasonographic (US) visualization of the subcostal nerve just caudate to the 12th costa - Succes rate of US visualization of the subcostal nerve at location where the lateral cutaneous nerve is branching off - Success rate of US visualization of the subcostal lateral cutaneous nerve in its course through the external oblique muscle -Succes rate of relevant cutaneous anesthesia after subcostal nerve block - Succes rate of relevant cutaneous anesthesia after subcostal nerve block produced by the primary injection - Extent of the cutaneous area anesthetized after subcostal nerve block - Success rate of each of the incisions (cannulated screws, DHS, IM nail, anterior-, anterolateral- lateral- and posterior approach) in being completely covered by the cutaneous anesthesia after subcostal nerve block - Success rate of each of the incisions in being partly covered by the cutaneous anesthesia after subcostal nerve block -Rate of complete failure for each of the incisions to be covered by any cutaneous anesthesia after subcostal nerve block -Success rate of the LFCN block to produce a cutaneous area of anesthesia that is continous with the anesthetized cutaneous area after the subcostal nerve block on day one -Success rate of the LFCN block to produce a cutaneous area of anesthesia that is continous with the anesthetized cutaneous area after the subcostal nerve block on day one measured on a vertical line through the greater trochanter - Success rate of each of the incisions in being completely covered by the cutaneous anesthesia after subcostal nerve block and LFCN nerve block - Time needed to do the TFP block -Success rate of the TFP block with local anesthetic to produce a cutaneous area of anesthesia that is continous with the anesthetized cutaneous area after a LFCN block, compared to placebo, measured on a vertical line through the greater trochanter - Success rate of each of the incisions in being completely covered by the cutaneous anesthesia after LFCN nerve block and TFP block with local anesthetic, compared to placebo - Success rate of each of the incisions in being partly covered by the cutaneous anesthesia after LFCN nerve block and TFP block with local anesthetic, compared to placebo -Rate of complete failure for each of the incisions to be covered by any cutaneous anesthesia after LFCN nerve block and TFP block with local anesthetic, compared to placebo -Success rate of blockage of the iliohypogastric nerve after TFP block with local anesthetic, compared to placebo -Success rate of blockage of the subcostal nerve after TFP block with local anesthetic, compared to placebo -Extent of the cutaneous area anesthetized by the TFP block
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
30 minutes after relevant nerve blocks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | 4 |